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Abstract: The Massachusetts General Hospital Hairpulling Scale (MGH-HPS)
and the NIMH Trichotillomania Severity Scale (NIMH-TSS) are two widely
used measures of trichotillomania severity. Despite their popular use,
currently no empirically-supported guidelines exist to determine the degrees
of change on these scales that best indicate treatment response.
Determination of such criteria could aid in clinical decision-making by defining
clinically significant treatment response/recovery and producing accurate
power analyses for use in clinical trials research. Adults with trichotillomania
(N = 69) participated in a randomized controlled trial of psychotherapy and
were assessed before and after treatment. Response status was measured via
the Clinical Global Impressions-Improvement Scale, and remission status was
measured via the Clinical Global Impressions-Severity Scale. For treatment
response, a 45% reduction or 7-point raw score change on the MGH-HPS was
the best indicator of clinically significant treatment response, and on the
NIMH-TSS, a 30–40% reduction or 6-point raw score difference was most
effective cutoff. For disorder remission, a 55–60% reduction or 7-point raw
score change on the MGH-HPS was the best predictor, and on the NIMH-TSS,
a 65% reduction or 6-point raw score change was the best indicator of
disorder remission. Implications of these findings are discussed.
Keywords: Hair pulling, Trichotillomania, Obsessive-compulsive disorder,
Signal detection, Psychotherapy

1. Introduction
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Researchers have demonstrated the efficacy of various
treatments for reducing hair pulling in adults with Trichotillomania
(TTM; Bloch et al., 2007). Such studies typically utilize
psychometrically-validated measures of pulling severity (Grant et al.,
2009, Keuthen et al., 2012 and Woods et al., 2006), the most
common of which are the Massachusetts General Hospital Hairpulling
Scale (MGH-HPS; Keuthen et al., 1995) and the National Institutes of
Mental Health Trichotillomania Severity Scale (NIMH-TSS; Swedo et
al., 1989).
The MGH-HPS is a self-report measure and the NIMH-TSS is
clinician-rated. Both are dimensional scales that possess sensitivity to
change in TTM treatment studies (Diefenbach et al., 2005 and Swedo
et al., 1989). Although existing treatments have yielded statistically
significant changes in scores on both measures (Woods et al., 2006),
the magnitude of reductions needed to signify clinically significant
change is unclear.
When no clear cutoffs exist for a primary outcome measure,
establishing the clinical significance of change requires the
incorporation of additional information. For instance, clinicians might
rely on a combination of qualitative and quantitative data to gauge
improvement, thereby interpreting scores based on clinical judgment.
An example of this type of measurement is the Clinical Global
Impressions Scale (CGI; Guy, 1976), which consists of a severity index
(CGI-S) and treatment improvement index (CGI-I). The CGI is a
clinician-rated measure that incorporates multiple sources of data and
provides a clearly interpretable metric of holistic disorder severity and
treatment response. The CGI is also widely used in clinical trials
(Bandelow et al., 2006, Leon et al., 1993, Leucht and Engel, 2006,
Leucht et al., 2005, Spielmans and McFall, 2006 and Zaider et al.,
2003) and has been used for trichotillomania (e.g., Keuthen et al.,
2011 and Keuthen et al., 2012). To best determine the level of
symptom reduction as measured by popular assessments of hair
pulling severity, one could measure the points at which score
reductions on dimensional measures (i.e., MGH-HPS and NIMH-TSS)
converge best with the thresholds of clinical significance on the CGI-I
and CGI-S.
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Developing guidelines for clinically significant change on the
MGH-HPS and NIMH-TSS would have numerous benefits in both
research and clinical practice. When designing a randomized controlled
trial (RCT), one ensures that the study is adequately powered to
detect the desired effect size (Cohen, 1988 and Kraemer and
Thiemann, 1987). Recent recommendations by Kraemer and Kupfer
(2006) suggest that the level of power needed in studies be based on
the determination of clinically significant effects. The current study
attempts to identify clinically significant cutoff criteria in commonly
used TTM outcome measures, so that future studies can better
approximate the power needed to identify clinically significant effects.
These guidelines will also have clinical utility, as a clinically meaningful
change score can give therapists a target for change and can indicate
the point at which change has become significant.
A recent study examined the ability of changes in the MGH-HPS
and another clinician-rated measure of hair pulling severity, the
Psychiatric Institute Trichotillomania Scale (PITS; Winchel et al., 1992)
to predict various meaningful outcomes (Nelson et al., 2014). Various
potential clinical predictors were used, including Jacobson and Truax’s
(1991) clinically significant change criteria (i.e., 1.96 times the reliable
change index plus a post-treatment score that was two standard
deviations below the dysfunctional population mean), complete
abstinence from pulling (defined as a score of 0 on MGH-HPS item 4),
25% reduction on the MGH-HPS or PITS, and the recovery criterion
alone (e.g., score of ≤9 on the MGH-HPS or ≤14 on the PITS). Posttreatment abstinence from hair pulling and the MGH-HPS 25%
reduction predicted several positive outcomes (i.e., decision to
successfully end treatment at step 2 in the stepped-care clinical trial,
treatment satisfaction, and quality of life at 3-month follow-up), but
the Jacobson and Truax clinically significant change criteria on the
MGH-HPS predicted only quality of life at 3-month follow-up. The 25%
PITS reduction predicted no outcomes, whereas the PITS-based
recovery criterion predicted decision to end treatment and the
Jacobson and Truax clinically significant change criteria on the PITS
predicted absence of TTM diagnosis at 3-month follow-up. As such, it
appears that the ways of defining different clinical predictors leads to
differential prediction of various indices of treatment response.
However, no cutoff stands out as the most efficient indicator of
treatment response. Determining more efficient cutoffs might be
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achieved through approaches that are not constrained by rigid
definitions of these cutoffs, such as by testing the validity and
efficiency of numerous score reductions as they converge with welldefined measures of clinically significant change (i.e., the CGI).
Indeed, five studies have performed signal detection analyses to
determine such cutoffs with related conditions, such as obsessivecompulsive disorder and tic disorders. Investigators found that a 25%
decrease on the Children’s Yale-Brown Obsessive-Compulsive Scale
was most efficient at predicting treatment response in childhood OCD,
as measured by the CGI-I and the Child Obsessive-Compulsive Impact
Scale (Storch, Lewin, De Nadai, & Murphy, 2010), while others found
between 30 and 35% reductions on the Yale-Brown ObsessiveCompulsive Scale were most efficient in predicting adult OCD
treatment response as measured by the CGI-I (Lewin et al.,
2011 and Tolin et al., 2005). Likewise, a 35% reduction or 6–7 point
raw score decrease on the Yale Global Tic Severity Scale (YGTSS) was
found to best predict treatment response in Tourette syndrome as
measured by the CGI-I (Storch et al., 2011), whereas Jeon et al.
(2013) found that a 25% reduction on the YGTSS optimally predicted
positive response as measured by the CGI-I in both children and
adults with tic disorders. Although these studies allow clinicians to
accurately predict which clients demonstrate clinically significant
treatment response, no studies have determined reductions on
dimensional measures of obsessive-compulsive related disorders that
optimally predict disorder recovery. As was done in the Nelson et al.
study on measures of treatment response in TTM, researchers have
argued that estimates of clinical significance should calculate the
propensity of a treatment to facilitate a decrease in symptoms within
clinical individuals to those resembling normative levels ( Jacobson &
Truax, 1991). Thus, it would be useful to determine if certain levels of
symptom reduction on dimensional scales correspond to both reliable
change and recovery of normal functioning.
The present study sought to replicate the methods of previous
signal detection analyses in defining treatment response for adults
with TTM using both the MGH-HPS and the NIMH-TSS. In order to
determine clinically significant treatment response, we used the CGI-I
as the criterion measure. Similarly, the CGI-S was used as the
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criterion measure of TTM recovery. No a priori hypotheses were made
with regard to optimal cutoff points on the measures analyzed.

2. Method
2.1. Participants
Although 85 participants were randomized into the clinical trial,
only those who completed treatment were included in the present
study. Participants were 69 adults (62 females) diagnosed with TTM
whose ages ranged from 18 to 61 (M = 35.86, SD = 13.05). The
sample was 85.5% Caucasian, 11.6% African–American, and 2.9%
“other.” Data were collected as part of a randomized controlled trial for
psychotherapy for adults with TTM (Woods et al., in preparation). Both
therapeutic conditions tested in the trial (i.e., Acceptance-Enhanced
Behavior Therapy and psychoeducation plus supportive
psychotherapy) are included in these analyses. Also, only participants
who completed both the baseline and post-treatment assessments
were included. At baseline, mean scores on the MGH-HPS and NIMHTSS were 16.99 (SD = 4.68, Range = 8–26) and 14.54 (SD = 3.72,
Range = 6–21), respectively.
Inclusion criteria were: (1) a current DSM-IV-TR diagnosis of
TTM (2) an MGH-HPS score of >12, (3) a Wechsler Test of Adult
Reading score of >85, (4) age 18–65, (5) English fluency, (6) able to
maintain outpatient status, (7) no initiation or change in psychotropic
medication status or dosage for eight weeks preceding participation or
during the study, (8) not currently receiving psychotherapy for any
condition, and (9) completed all 10 sessions of treatment.
Exclusion criteria included: (1) diagnosis of bipolar disorder,
psychotic disorder, substance dependence (except nicotine
dependence), or pervasive developmental disorder, and (2) severe
mood or anxiety problems with potential suicidality. In addition,
individuals who endorsed ingesting their hair after pulling were eligible
for participation only after they had received a physical exam from
their primary care physician.

2.2. Treatment
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Participants were randomized to receive either AcceptanceEnhanced Behavior Therapy (AEBT; n = 35) or psychoeducation and
supportive psychotherapy (PST; n = 34) control. For a detailed
description of AEBT therapeutic techniques, see Woods and Twohig
(2008). The PST protocol was derived from Pinsker (1997). Inclusion
criteria mandated that participants maintain a stable dose on any
medications for the 8 weeks prior to and during the study. In total,
29% were currently taking a psychotropic medication during the study,
but only 2.9% were prescribed medication for TTM. Of the sample,
21.7% were taking selective serotonin reuptake inhibitors, 7.2% were
taking other antidepressants (e.g., tricyclics), 7.2% were taking
psychostimulants, 2.9% benzodiazepines, 2.9% reported taking
atypical neuroleptics, and 1 person (1.4%) was taking Hydroxyzine (an
antihistamine) for anxiety. One-fifth of the total sample (20.3%) were
taking only one medication, while 4.3% were taking two medications
and 4.3% were taking three or four medications.

2.3. Measures
The Structured Clinical Interview for DSM-IV Axis-I Disorders,
Patient Edition (SCID-P; First, Spitzer, Gibbon, & Williams, 1996) was
used to screen for psychiatric comorbidities. Additionally, the
Trichotillomania Diagnostic Interview (TDI; Rothbaum & Ninan, 1994)
was employed for obtaining TTM diagnosis.
The MGH-HPS has demonstrated adequate psychometric
properties (Diefenbach et al., 2005, Keuthen et al.,
1995 and O'Sullivan et al., 1995). It consists of seven items that are
scored on a 0–4 Likert scale, resulting in total scores ranging from 0 to
28, with higher scores indicating greater hair pulling severity. The
MGH-HPS was administered at baseline and post-treatment.
The NIMH-TSS has demonstrated adequate psychometric
properties in adults (Diefenbach et al., 2005 and Swedo et al., 1989).
Interviewers using the NIMH-TSS ask questions about time spent
pulling, resistance to urges, distress, and impairment, resulting in total
scores that range from 0 to 25. The NIMH-TSS was also administered
at baseline and post-treatment.
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The CGI was developed to provide a brief, stand-alone measure
of clinician-rated global treatment response and disorder severity in
NIMH-sponsored clinical trials (Guy, 1976). The CGI has evidence of
convergent validity on many symptom severity scales across many
psychiatric conditions in both pharmacological and psychosocial
treatment paradigms (Bandelow et al., 2006, Leon et al., 1993, Leucht
and Engel, 2006, Leucht et al., 2005, Spielmans and McFall,
2006 and Zaider et al., 2003) and has been used for TTM (e.g.,
Keuthen et al., 2011 and Keuthen et al., 2012). The CGI-I is a singleitem clinician-rated measure that assesses the overall improvement of
a person’s condition throughout treatment on an 8-point Likert scale
(Range = 1–8). Scores of 1 and 2 (very much improved and much
improved) are indicators of treatment response while all greater scores
indicate treatment non-response. Similarly, the CGI-S is a single-term
clinician rated measure that assesses the overall severity of a person’s
condition on an 8-point Likert scale (Range = 1–8). Scores of 1 and 2
(normal, not at all ill and borderline ill) are indicators of no TTM
diagnosis or mild TTM symptoms, while all greater scores indicate
significant TTM symptoms. The CGI-I and CGI-S were administered at
post-treatment. To ensure the validity of CGI ratings, masked
independent evaluators were trained in CGI administration and met
weekly with the Principal Investigator (D.W.W.) to discuss and review
taped assessments.

2.4. Procedure
Adults with TTM were recruited to participate in a randomized
controlled trial of psychotherapy for TTM via local newspaper ads,
public transportation flyers, newsletter and website advertisements via
the Trichotillomania Learning Center (www.trich.org), and clinic
referrals at a TTM specialty clinic.
Potential participants were screened by telephone. All callers to
a TTM clinic were provided information about the study and screened
for possible participation. If the participant appeared to be eligible and
interested, he or she was scheduled for an initial clinic visit, during
which consent was obtained and inclusion/exclusion criteria checked.
Participants deemed ineligible or those not wishing to participate were
referred for standard clinical services. Potential participants (N = 274)
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were screened via telephone. The baseline sample consisted of 91
persons, of which 85 were randomized and 16 participants were lost
throughout treatment, resulting in a post-treatment sample of 69
persons. For additional details regarding screening, exclusions, and
attrition, see Woods et al. (in preparation). Additionally, all clinicianrated instruments were administered by masters- and doctoral-level
independent evaluators who were masked to treatment condition. The
CGI scales and the NIMH-TSS are rated using a semi-structured
procedure.
IRB approval for this project was obtained at Texas A&M
University (IRB2013-3025) and the University of Wisconsin-Milwaukee
(IRB09.039). The study is publicly listed on ClinicalTrials.gov
(#NCT00872742), and was performed in compliance with the Code of
Ethics of the World Medical Association (Declaration of Helsinki).

2.5. Analyses
The goal of the current study was to find the levels of symptom
reduction needed on the MGH-HPS and NIMH-TSS that most optimally
predicted treatment response (i.e., CGI-I < 3) and disorder recovery
(i.e., CGI-S < 3). Both percent reductions and raw score reductions
(from baseline to post-treatment) on each measure were used to
predict the CGI-I and CGI-S. The authors chose not to define clinically
significant treatment response as meeting both significant change on
the CGI-I and significant recovery on the CGI-S. This decision was due
to the fact that although many individuals with TTM wish to achieve
complete abstinence from pulling, many others are satisfied with a
significant reduction in hair pulling (Woods & Houghton, 2014). Thus,
persons with severe TTM who show clinically meaningful symptom
reductions but do not achieve complete recovery should not be
discounted as having not responded to treatment, whereas those
persons would be ignored by definitions of clinically significant
treatment response that require both change and recovery.
Additionally, performing such analyses separately allows a more
detailed interpretation of the assessment of change in treatment for
TTM.
Receiver operating characteristic (ROC) methods (Swets &
Pickett, 1982), which have been previously used for these purposes
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(Storch et al., 2011), were used in the present study. ROC methods
focus on the predictive validity of psychological tests, using statistics
such as number of true positives, true negatives, false positives, and
false negatives. In testing percent reduction cutoffs, we created cutoffs
at every 5% interval between 5% and 70%. For raw scores, point
reductions between 1 and 11 were evaluated. Following the
methodology of Storch et al. (2011), our analysis operationalized score
reductions as raters, then tested which reduction (or “rater”) has the
best psychometric efficiency for detecting clinical response to
treatment.
ROC analyses incorporate several psychometric properties of
assessments, including sensitivity, specificity, positive predictive
power, negative predictive power, and efficiency. Sensitivity is defined
as a measure’s ability to detect the presence of a given criterion (in
this study, clinically significant treatment response or disorder
recovery). Alternatively, specificity is defined as a test’s ability to
detect the absence of a given criterion. Positive predictive power (PPP)
reflects the proportion of correctly predicted positive results provided
by a diagnostic test, whereas negative predictive power (NPP) reflects
the proportion of correctly predicted negative results. Efficiency can be
described as the accuracy of a test, such that a given cutoff or rating
on a test “agrees” with another definitive test.
Even the most psychometrically sound tests contain at least
minimal measurement error (in this study, the CGI-I and CGI-S).
Therefore, a weighted Kappa statistic was used to correct for such
error when assessing the quality of efficiency (Kraemer,
1992 and Kraemer et al., 2002). Weighted kappa statistics examine
the agreement between measures but correct for measurement error
in a manner similar to the method by which Cohen’s Kappa accounts
for chance agreement in inter-observer reliability. For this analysis, the
K(0.5) statistic was used, which ranges from 0.00–1.00. A value of 0 is
indicative of agreement purely by chance, and a value of 1 reflects
perfect classification (i.e., all true positives and true negatives). The
K(0.5) statistic measures the quality of efficiency while weighing
sensitivity and specificity equally, and was used in order to generalize
results across contexts, following the approach of Storch et al. (2011).
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3. Results
3.1. Adequacy of measures for signal detection analysis
Reliability analyses were performed in order to determine
whether the MGH-HPS and NIMH-TSS were suitable for signal
detection analysis. Test-retest reliability correlations were computed
from the screening assessment date to the baseline assessment date,
a time period that lasted, on average, 11.81 days (SD = 6.04). The
MGH-HPS test-retest reliability coefficient was 0.45 (p < 0.001) and
the NIMH-TSS reliability coefficient was 0.65 (p < 0.001), which are
comparable to reliability coefficients of TTM severity instruments at
similar intervals ( McGuire et al., 2012 and Stanley et al., 1993).
Because these measures assess hair-pulling severity during the
previous week, and because hair pulling is a constantly fluctuating
behavior, we deemed these reliability coefficients to be acceptable and
that the measures were suitable for signal detection analysis.

3.2. Determining treatment response and recovery
based on MGH-HPS percentage reduction
Table 1 shows ROC and quality assurance statistics for assessing
performance of MGH-HPS percent reduction cutoffs in detecting clinical
response and recovery. Results showed that 45% reductions optimally
predicted treatment response (as measured by the K(0.5) statistic),
with the predictive value of a positive test at 0.90 and predictive value
of a negative test at 0.79. Recovery from TTM was optimally predicted
by 55–60% reductions, which showed predictive values of a positive
test at 0.79 and 0.83 and predictive values of negative tests at 0.86
and 0.83, respectively.
Table 1. Signal detection analysis of the prediction of clinical response and
recovery at increasing Massachusetts General Hospital Hairpulling Scale
(MGH-HPS) total percent reduction cutoff scores.
MGH-HPS
reduction
(%)

Sensitivity Specificity

Positive
predictive
power

Negative
predictive
power

Efficiency

K(0.5)

Predicting treatment response (based on CGI-I)
≥5

0.98

0.31

0.70

0.89

0.72

0.33

≥10

0.95

0.31

0.70

0.80

0.71

0.3
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MGH-HPS
reduction
(%)

Sensitivity Specificity

Positive
predictive
power

Negative
predictive
power

Efficiency

K(0.5)

≥15

0.93

0.39

0.72

0.77

0.72

0.35

≥20

0.93

0.46

0.74

0.80

0.75

0.43

≥25

0.91

0.54

0.77

0.78

0.77

0.47

≥30

0.91

0.62

0.80

0.80

0.80

0.55

≥35

0.88

0.73

0.84

0.79

0.83

0.62

≥40

0.88

0.81

0.88

0.81

0.86

0.69

≥45

0.86

0.85

0.90

0.79

0.86

0.70

≥50

0.84

0.85

0.90

0.76

0.84

0.67

≥55

0.70

0.89

0.91

0.64

0.77

0.54

≥60

0.63

0.92

0.93

0.60

0.74

0.50

≥65

0.47

0.96

0.95

0.52

0.65

0.37

≥70

0.35

1

1

0.48

0.59

0.29

Predicting recovery (based on CGI-S)
≥5

1

0.24

0.52

1

0.58

0.22

≥10

1

0.26

0.53

1

0.59

0.24

≥15

1

0.34

0.55

1

0.64

0.32

≥20

1

0.40

0.57

1

0.67

0.37

≥25

0.97

0.45

0.59

0.94

0.68

0.39

≥30

0.97

0.50

0.61

0.95

0.71

0.44

≥35

0.94

0.58

0.64

0.92

0.74

0.49

≥40

0.94

0.63

0.67

0.92

0.77

0.55

≥45

0.94

0.68

0.71

0.93

0.80

0.60

≥50

0.94

0.71

0.73

0.93

0.81

0.63

≥55

0.84

0.82

0.79

0.86

0.83

0.65

≥60

0.77

0.87

0.83

0.83

0.83

0.65

≥65

0.58

0.92

0.86

0.73

0.77

0.52

≥70

0.045

0.97

0.93

0.69

0.74

0.45

3.3. Determining treatment response and recovery
based on MGH-HPS raw score reduction
Table 2 shows ROC and quality assurance statistics for assessing
performance of MGH-HPS point reduction cutoffs in detecting clinical
response and recovery. These results indicate that a seven-point raw
score reduction was most efficient at identifying treatment response.
PPP at the seven-point level was 0.82 while NPP was 0.72. Similarly,
the seven-point raw score reduction was most efficient at identifying
recovery, with PPP and NPP at 0.64 and 0.88, respectively. Of note,
the K(0.5) values reflect agreement that is not as strong as when the
MGH-HPS percent reductions are used, and the peak K(0.5) value for
raw score reductions predicting recovery (0.46) is lower than the peak
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raw score reductions predicting response (0.53). As such, raw score
reductions, particularly predicting recovery, might not be very efficient
prediction tools.
Table 2. Signal detection analysis of the prediction of clinical response and
recovery at increasing Massachusetts General Hospital Hairpulling Scale
(MGH-HPS) total raw score cutoff scores.
MGH-HPS
reduction
(%)

Sensitivity Specificity

Positive
predictive
power

Negative
predictive
power

Efficiency

K(0.5)

Predicting treatment response (based on CGI-I)
≥1

0.98

0.31

0.70

0.89

0.72

0.33

≥2

0.93

0.35

0.70

0.75

0.71

0.31

≥3

0.93

0.39

0.71

0.77

0.72

0.35

≥4

0.88

0.54

0.76

0.74

0.75

0.45

≥5

0.88

0.54

0.76

0.74

0.75

0.45

≥6

0.88

0.62

0.79

0.76

0.78

0.52

≥7

0.84

0.69

0.82

0.72

0.78

0.53

≥8

0.70

0.77

0.83

0.61

0.72

0.44

≥9

0.70

0.85

0.88

0.63

0.75

0.51

≥10

0.61

0.89

0.9

0.58

0.71

0.44

≥11

0.54

0.89

0.89

0.54

0.66

0.37

Predicting recovery (based on CGI-S)
≥1

1

0.24

0.52

1

0.58

0.22

≥2

1

0.32

0.54

1

0.62

0.29

≥3

1

0.34

0.55

1

0.64

0.32

≥4

0.94

0.45

0.58

0.90

0.67

0.36

≥5

0.94

0.45

0.58

0.90

0.67

0.36

≥6

0.94

0.50

0.60

0.91

0.70

0.42

≥7

0.90

0.58

0.64

0.88

0.72

0.46

≥8

0.71

0.63

0.61

0.73

0.67

0.34

≥9

0.71

0.68

0.65

0.74

0.70

0.39

≥10

0.61

0.74

0.66

0.74

0.68

0.35

≥11

0.55

0.76

0.65

0.67

0.67

0.32

3.4. Determining treatment response and recovery
based on NIMH-TSS percent reduction
Table 3 shows ROC and quality assurance statistics for assessing
performance of NIMH-TSS percent reductions cutoffs in detecting
treatment response and recovery. Results indicate that a 30–40%
reduction in scores maximally predict clinical response, with PPP and
NPP at 0.89 and 0.84 for all percentiles within that range. Recovery
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from TTM was optimally predicted by a much higher percentile
reduction, 65%, which showed PPP of 0.96 and NPP of 0.84.
Table 3. Signal detection analysis of the prediction of clinical response and
recovery at increasing National Institutes of Mental Health Trichotillomania
Severity Scale (NIMH-TSS) total percent reduction cutoff scores.
NIMH-TSS
reduction
(%)

Sensitivity Specificity

Positive
predictive
power

Negative
predictive
power

Efficiency

K(0.5)

Predicting treatment response (based on CGI-I)
≥5

1

0.27

0.69

1

0.72

0.32

≥10

1

0.42

0.74

1

0.78

0.48

≥15

0.98

0.50

0.76

0.93

0.80

0.53

≥20

0.98

0.54

0.78

0.93

0.81

0.56

≥25

0.93

0.58

0.78

0.83

0.80

0.54

≥30

0.91

0.81

0.89

0.84

0.87

0.72

≥35

0.91

0.81

0.89

0.84

0.87

0.72

≥40

0.91

0.81

0.89

0.84

0.87

0.72

≥45

0.88

0.81

0.88

0.81

0.86

0.69

≥50

0.86

0.85

0.90

0.79

0.86

0.70

≥55

0.72

0.89

0.91

0.67

0.78

0.57

≥60

0.63

0.96

0.96

0.61

0.75

0.53

≥65

0.56

0.96

0.96

0.57

0.71

0.46

≥70

0.42

0.96

0.95

0.50

0.62

0.32

Predicting recovery (based on CGI-S)
≥5

1

0.18

0.50

1

0.55

0.17

≥10

1

0.30

0.53

1

0.61

0.27

≥15

0.97

0.34

0.55

0.93

0.62

0.29

≥20

0.97

0.37

0.56

0.93

0.64

0.32

≥25

0.97

0.45

0.59

0.94

0.68

0.39

≥30

0.97

0.63

0.68

0.96

0.78

0.58

≥35

0.97

0.63

0.68

0.96

0.78

0.58

≥40

0.97

0.63

0.68

0.96

0.78

0.58

≥45

0.94

0.63

0.67

0.92

0.77

0.55

≥50

0.94

0.68

0.71

0.93

0.80

0.60

≥55

0.87

0.82

0.79

0.89

0.84

0.68

≥60

0.81

0.92

0.89

0.85

0.86

0.73

≥65

0.77

0.97

0.96

0.84

0.88

0.76

≥70

0.61

1

1

0.76

0.82

0.64

≥75

0.48

1

1

0.70

0.77

0.51
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3.5. Determining treatment response and recovery
based on NIMH-TSS raw score reduction
Table 4 shows ROC and quality assurance statistics for assessing
performance of NIMH-TSS raw score reduction cutoffs in detecting
treatment response and recovery. Results show that a six-point
reduction on this measure maximally predicts clinical response, with
PPP and NPP at 0.88 and 0.78, respectively. Similarly, the six-point
reduction also optimally predicted recovery, with PPP at 0.69 and NPP
0.93. Of note, the K(0.5) values in this analysis are considerably lower
than those shown when using the NIMH-TSS percent reductions,
appearing to behave similarly to the relationship between percent
reductions and raw cutoffs on the MGH-HPS.
Table 4. Signal detection analysis of the prediction of clinical response and
recovery at increasing National Institutes of Mental Health Trichotillomania
Severity Scale (NIMH-TSS) total point reduction cutoff scores.
NIMH-TSS
reduction
(%)

Sensitivity

Specificity

Positive
predictive
power

Negative
predictive
power

Efficiency

K(0.5)

Predicting treatment response (based on CGI-I)
≥1

1

0.27

0.69

1

0.72

0.32

≥2

0.98

0.46

0.75

0.92

0.78

0.49

≥3

0.98

0.50

0.76

0.93

0.80

0.53

≥4

0.93

0.62

0.80

0.84

0.81

0.58

≥5

0.88

0.73

0.84

0.79

0.83

0.62

≥6

0.86

0.81

0.88

0.78

0.84

0.66

≥7

0.77

0.81

0.87

0.68

0.78

0.55

≥8

0.70

0.81

0.86

0.62

0.74

0.48

≥9

0.61

0.85

0.87

0.56

0.70

0.41

≥10

0.42

0.92

0.90

0.49

0.61

0.29

≥11

0.33

0.92

0.88

0.45

0.55

0.21

Predicting recovery (based on CGI-S)
≥1

1

0.18

0.5

1

0.55

0.17

≥2

0.97

0.32

0.54

0.92

0.61

0.26

≥3

0.97

0.34

0.55

0.93

0.62

0.29

≥4

0.97

0.47

0.6

0.95

0.7

0.42

≥5

0.94

0.58

0.64

0.92

0.74

0.49

≥6

0.94

0.66

0.69

0.93

0.78

0.58

≥7

0.84

0.68

0.68

0.84

0.75

0.51

≥8

0.74

0.68

0.66

0.77

0.71

0.42

≥9

0.68

0.76

0.7

0.74

0.72

0.44

≥10

0.48

0.87

0.75

0.67

0.7

0.36
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NIMH-TSS
reduction
(%)
≥11

Sensitivity
0.42

Specificity
0.92

Positive
predictive
power
0.81

Negative
predictive
power
0.66

Efficiency
0.7

K(0.5)
0.36

4. Discussion
The purpose of this investigation was to identify maximally
efficient cutoff levels of two widely used measures of TTM severity. For
predicting treatment response, the most efficient reductions on the
MGH-HPS were found to be 45% or seven-point reductions, and the
most efficient reductions on the NIMH-TSS were found to be 30–40%
or six-points. For predicting recovery from TTM, the most efficient
reductions on the MGH-HPS were found to be 55–60% or seven-point
reductions, and the most efficient reductions on the NIMH-TSS were
found to be 65% or six-points. We offer these empirically derived
cutoffs so that future researchers and clinicians might utilize them to
maximize their predictive validity in labeling TTM patients as clinically
significant treatment responders. Likewise, researchers who develop
clinical trials using these outcome measures should power their studies
to ensure that these clinically meaningful effect sizes can be detected.
It might be expected that the degree of score reduction needed
to achieve response might be less than that needed to achieve
recovery from TTM. However, results showed that while percentage
reductions where higher when predicting recovery than when
predicting response, the raw score cutoffs did not change. This result
might be explained by several factors. When the CGI-I is rated, trained
evaluators consider the degree of change shown by the individual with
reference to their baseline disorder severity. Conversely, the CGI-S
ratings are static categories of TTM severity. An individual who enters
treatment in the severe range of severity but exits treatment in the
moderate range could be seen as having the same degree of
improvement as an individual who enters treatment in the moderate
range and exits in the mild, or undiagnosed, range. However,
achieving recovery requires a greater degree of change for those who
start treatment in the severe range as compared to those who start in
the moderate range, meaning that individuals in the latter group are
more likely to achieve recovery than those in the former group. For
example, an MGH-HPS reduction from 12 to 5 conveys a very different
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clinical picture than one from 26 to 19. Both are 7-point reductions,
but the former would be considered to have significantly improved and
recovered while the latter has just significantly improved. If we were
instead measuring the same two hypothetical individuals’ response by
percent reduction, the first would constitute a 58% reduction while the
second would only represent a reduction of 27%. As such, the
relatively high percent changes but small raw score change shown by
those who recover from moderately severe pulling would be overrepresented in those who recover from TTM and cause the difference
in percentile reductions seen between predictions of response and
recovery.
The same problem could have also conversely influenced the
finding that the efficiency of both measures was notably higher when
using percent reductions rather than raw score reductions. Indeed,
while floor effects do bias the interpretation of percent reductions as
predicting response versus recovery, they do provide an index of the
degree of change relative to baseline levels. Raw score differences
contain no information about baseline disorder severity, and thus
might be less efficient at predicting criterion indices of treatment
response and recovery. Still, additional factors might also influence the
effectiveness of both raw score and percent reductions in predicting
treatment response and recovery from TTM, such as regression toward
the mean. With these scaling limitations in mind, clinicians should
consider both raw score and percent reductions when determining
whether a particular client has significantly responded to treatment or
recovered from TTM. Researchers should also consider which criterion
of improvement is most important to use when powering a study, as
judgments of treatment efficacy could be expected to significantly vary
depending on this question (Nelson et al., 2014).
This study identified the most optimal cutoffs based on their
agreement with a criterion outcome measure, but the cutoff
percentages and score reductions surrounding the most optimal cutoffs
did not drop off steeply. This suggests that the incremental efficiency
of this study's proposed cutoffs relative to nearby cutoffs is low, and
other studies might find similar but not exact replications. In order to
determine if these cutoffs generalize to other samples, multiple
replications are required. It is also important that the cutoffs
recommended in the current study be placed into clinical context. Hair
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pulling is a constantly fluctuating behavior, and scores on the MGHHPS and NIMH-TSS can vary over the passage of time. Our analyses
indicated that certain raw score and percentage reductions could best
identify persons who responded to treatment, but clinicians who treat
TTM should consider these cutoffs alongside other clinical data.
In addition to the cutoff scores generated, the study had a
number of methodological strengths, including a relatively large
sample (for a disorder of low prevalence), administration of multiple
treatments, and the use of multiple measures with separate response
formats. Furthermore, we examined two widely used measures of TTM
symptom severity, one being self-report and the other clinicianadministered. Results of this analysis are thus applicable in a variety of
assessment contexts, whether one wishes to use only one method or
collect multiple sources of information.
The study had several limitations. First, the analysis could have
been strengthened through the inclusion of additional therapeutic
conditions, such as pharmacotherapy. Given that meta-analyses have
consistently shown that drug treatments of TTM are less effective than
behavioral treatments (Bloch et al., 2007 and McGuire et al., 2014),
this might be considered a minor limitation. Second, the findings could
have been enhanced by an analysis of moderating variables, such as
gender or age. It is possible that such factors might predict different
degrees of symptom reduction necessary for clinical response.
However, the sample was heavily biased towards females (89.85%),
as is common in treatment trials of TTM (Christenson, Mackenzie, &
Mitchell, 1994). The highly unequal cell sizes would have made such
analyses inappropriate for gender. Third, adults were the only age
group studied in this intervention, and clinically significant symptom
reductions might be different in children and adolescents. Comparable
analyses within pediatric populations are needed to examine the
generalizability of these cutoffs for all age groups.
Despite these limitations, the current study represents the first
effort at quantifying clinically significant dimensional reductions in hair
pulling severity. Given that the MGH-HPS and NIMH-TSS are widely
used in TTM research and treatment, researchers and providers can
make use of the guidelines for assessing treatment response outlined
in this study.
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